SEC Form 4 · accession 0001493152-26-031403
PROVECTUS BIOPHARMACEUTICALS, INC. · PVCT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Lacey III
Director
Period of report
Jun 30, 2026
Accepted (ET)
Jun 30, 2026 · 9:20 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000315545
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series D-1 Convertible Preferred StockF1,F2 | — | Jun 30, 2026 | A | 48,917 | A | Jun 30, 2026 | — | Common Stock | 489,170 | 228,509 | D |
Explanation of responses
- F1Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
- F2The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.